Purple Agrotech Industries to Review Q2 FY27 Results November 5
Key highlights
- Purple Agrotech's board meeting to consider Q2 FY27 and H1 FY27 results is scheduled for November 5, 2026.
- Purple Agrotech reported a Q1 FY27 net profit of ₹0.03 crore, down 69.7% year on year.
- Purple Agrotech reported Q1 FY27 sales of ₹1.41 crore and operating profit of ₹0.03 crore.
- Purple Agrotech reported Q4 FY26 sales of ₹20.00 crore and a net loss of ₹0.01 crore.
powered by IRIS

Purple Agrotech Industries Limited will consider its unaudited standalone results for Q2 FY27 and the half-year ended September 30, 2026, at a board meeting on November 5, following a Q1 FY27 net profit of ₹0.03 crore.
Know Purple Agrotech Industries inside out
Results, valuation, peers and who's buying, in one view.
What will Purple Agrotech consider at its November 5 board meeting?
Purple Agrotech will consider and approve unaudited standalone financial results for the quarter and half-year ended September 30, 2026. The company informed BSE on November 2 that its board of directors is scheduled to meet on November 5, 2026.
The disclosure is an advance intimation of the meeting rather than an earnings announcement. It does not provide Q2 FY27 revenue, profit, margin, balance-sheet, or cash-flow figures. Those details will become available only after the board considers and releases the results.
The agenda also allows the board to discuss other matters. However, the filing does not specify any transaction, fundraising proposal, operational decision, or corporate action beyond the planned review of the unaudited standalone results.
Which reporting period will Purple Agrotech disclose?
Purple Agrotech will disclose standalone performance for the three months ended September 30, 2026, along with the financial results for the first half of FY27. The Q2 period follows the company’s June 2026 quarter, for which results were considered by the board on August 14, 2026.
Standalone results cover the financial performance of the listed company itself. The BSE intimation specifically refers to unaudited standalone numbers, so investors should distinguish them from consolidated financial results where applicable.
The company had previously informed the exchange about its Q1 FY27 board meeting and later submitted newspaper publication related to the unaudited results for the quarter ended June 30, 2026. The November meeting continues that quarterly disclosure cycle.
What does Purple Agrotech's recent financial record show?
Purple Agrotech reported net profit of ₹0.03 crore in Q1 FY27, down 69.7% year on year according to the provided results update. Quarterly data for the June 2026 period show sales of ₹1.41 crore, expenses of ₹1.38 crore, and operating profit of ₹0.03 crore.
The June-quarter operating profit margin was 2.13%. The reported earnings per share for that quarter was ₹0.03. These figures provide the immediately preceding quarterly reference point ahead of the September-quarter release.
The March 2026 quarter showed a different operating scale. Sales were ₹20.00 crore and expenses were ₹20.24 crore, resulting in an operating loss of ₹0.24 crore and an operating margin of negative 1.20%. A results update described the quarter as recording a net loss of ₹0.01 crore.
The available quarterly table shows zero sales across several quarters before March 2026. The return of reported sales in the March and June 2026 quarters is therefore an important context for assessing the Q2 FY27 release. But the meeting notice itself offers no indication of whether sales, margins, or profitability improved or weakened in the September quarter.
Got a follow-up? Ask IRIS
Why do the Q2 FY27 results matter for investors?
The Q2 FY27 results matter because they will show whether Purple Agrotech sustained reported revenue after the ₹20.00 crore sales figure in Q4 FY26 and the lower ₹1.41 crore sales figure in Q1 FY27. The comparison will help investors assess the variability in the company’s recent quarterly operating performance.
Investors can examine revenue, expenses, operating profit or loss, net profit or loss, and earnings per share once the company releases the results. The half-year statement will also provide a combined view of the June and September 2026 quarters, subject to the disclosures made by the company.
The filing states that the insider trading window will reopen 48 hours after the results are disclosed. Such trading-window controls are used around the release of unpublished price-sensitive financial information. The announcement does not disclose any share-price impact or market reaction.
What should investors compare after the results are released?
Investors should compare the September-quarter sales and expenses with the ₹1.41 crore and ₹1.38 crore respectively reported for June 2026. They can also assess whether operating profitability remains positive after the June-quarter operating profit of ₹0.03 crore.
A comparison with the March 2026 quarter may provide further perspective, although its sales base of ₹20.00 crore was substantially higher than the June-quarter figure. The most useful review will depend on the complete Q2 statement, including notes to accounts and any limited review information released with the results.
No forward guidance, target, dividend proposal, or management commentary was included in the November 2 board-meeting intimation. Until the financial results are filed, the confirmed event is limited to the scheduled board consideration of unaudited standalone Q2 and half-year results.
Conclusion
Purple Agrotech's November 5 board meeting is the next scheduled financial disclosure event for the company. It will place the September 2026 quarter alongside a recent record that included ₹20.00 crore of sales and a ₹0.01 crore net loss in Q4 FY26, followed by ₹1.41 crore of sales and ₹0.03 crore of net profit in Q1 FY27.
Investors should watch for the company’s reported Q2 FY27 revenue, expenses, operating margin, net profit or loss, and half-year figures after the board meeting. The company has also said that its insider trading window will reopen 48 hours after the results disclosure.


